

**Arvee Laboratories (India) Limited.**

Formerly known as Arvee Laboratories (India) Pvt. Ltd.  
403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,  
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.  
Phone: +91- 2717-430479 | +91- 2717-410819  
e-mail: info@arveelabs.com, Website: www.arveelabs.com  
CIN No. :- L24231GJ2012PLC068778.



**Date: 8th February, 2022**

**To  
National Stock Exchange of India  
Mumbai**

**Scrip Code: ARVEE**

**Sub: Outcome of Board Meeting held on 08.02.2022**


Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the Board of Directors in its meeting held on Tuesday, 8th February, 2022 have approved the unaudited results for the quarter and half year ended on 31<sup>st</sup> December, 2021.

We are also enclosing herewith the limited review report obtained from the statutory auditors of the Company.

The meeting started at **14.00** Hours and concluded at **15.00** Hours.

Kindly acknowledge the receipt of the same.

**For, Arvee Laboratories (India) Limited**

  
**Chief Financial Officer  
Saurin Ajitbhai Gandhi**



**Arvee Laboratories (India) Limited.**

Formerly known as Arvee Laboratories (India) Pvt. Ltd.  
 403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,  
 Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.  
 Phone: +91- 2717-430479 | +91- 2717-410819  
 e-mail: info@arveelabs.com, Website: www.arveelabs.com  
 CIN No. :- L24231GJ2012PLC068778.

**ARVEE LABORATORIES (INDIA) LIMITED**

CIN: L24231GJ2012PLC068778

Registered Office: 403, Entice, Nr. Jayantilal Park BRTS,  
Iskcon Bopal Road, Ambli, Ahmedabad - 380058

Tel : +91 – 2717-430479 || +91 – 2717-410819; Website : www.arveelabs.com; Email ID : compliance@arveelabs.com

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON DECEMBER 31, 2021**

(₹ in Lakhs, except per share data)

Sr. No.	Particulars	Quarter ended			Nine Month Ended		Year ended
		31/12/2021	30/09/2021	31/12/2020	31/12/2021	31/12/2020	31/03/2021
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1	Revenue from Operations	790.06	1,069.98	1,994.48	2,766.23	3,818.53	4,737.50
2	Other Income	12.25	7.29	12.84	25.28	56.90	58.48
3	<b>Total Revenue (1+2)</b>	<b>802.30</b>	<b>1,077.27</b>	<b>2,007.32</b>	<b>2,791.51</b>	<b>3,875.43</b>	<b>4,795.98</b>
4	<b>Expenses</b>						
	Cost of material consumed	583.15	475.21	1,086.49	1,578.27	2,298.29	2,907.47
	Purchase of stock-in-trade	-	-	-	-	-	-
	Changes in inventories of finished goods, work-in-progress and stock in trade	-157.08	151.13	339.16	-60.53	264.09	41.80
	Employee benefit Expenses	147.70	149.51	153.00	442.55	377.47	354.28
	Finance Costs	8.62	6.14	10.74	26.66	42.44	57.65
	Depreciation and amortisation expenses	37.65	66.72	58.51	170.24	179.15	240.66
	Other expenses	115.54	124.73	154.97	393.14	412.73	829.98
	<b>Total Expenses (4)</b>	<b>735.58</b>	<b>973.43</b>	<b>1,802.87</b>	<b>2,550.33</b>	<b>3,574.18</b>	<b>4,431.84</b>
5	<b>Profit / (Loss) before exceptional items and tax (1-4)</b>	<b>66.73</b>	<b>103.84</b>	<b>204.45</b>	<b>241.18</b>	<b>301.26</b>	<b>364.14</b>
6	Exceptional items	-	-	-	-	-	-
7	<b>Profit / (Loss) before tax (5-6)</b>	<b>66.73</b>	<b>103.84</b>	<b>204.45</b>	<b>241.18</b>	<b>301.26</b>	<b>364.14</b>
8	<b>Tax expense</b>						
	Current Tax	26.68	26.13	51.46	70.59	86.89	107.26
	Deferred Tax	-13.34	5.11	-	-8.23	-9.93	-10.85
9	<b>Profit / (Loss) for the period from continuing operations (7-8)</b>	<b>53.39</b>	<b>72.59</b>	<b>152.99</b>	<b>178.82</b>	<b>224.30</b>	<b>267.74</b>
10	Profit / (Loss) from discontinued operations	-	-	-	-	-	-
11	Tax Expense of discontinued operations	-	-	-	-	-	-
12	Profit / (Loss) from discontinued operations (after tax) (10-11)	-	-	-	-	-	-
13	<b>Profit / (Loss) for the period (9+12)</b>	<b>53.39</b>	<b>72.59</b>	<b>152.99</b>	<b>178.82</b>	<b>224.30</b>	<b>267.74</b>
14	Other Comprehensive Income						
	a. Items that will not be reclassified to profit or loss (Net of tax)	-	-	-	-	-	-
	b. Items that will be reclassified to profit or loss (Net of tax)	-	-	-	-	-	-
15	<b>Total Comprehensive Income for the period (13+14)</b>	<b>53.39</b>	<b>72.59</b>	<b>152.99</b>	<b>178.82</b>	<b>224.30</b>	<b>267.74</b>
	Paid-up equity share capital (Face Value of the Share Rs. 10/- each)	1,102.00	1,102.00	1,102.00	1,102.00	551.00	1,102.00
	Other Equity excluding Revaluation Reserve						1,041.82
16	<b>Earnings per equity share (for continuing operation)</b>						
	Basic	0.48	0.66	1.39	1.62	4.07	2.43
	Diluted	0.48	0.66	1.39	1.62	4.07	2.43
17	<b>Earnings per equity share (for discontinued operation)</b>						
	Basic	-	-	-	-	-	-
	Diluted	-	-	-	-	-	-
18	<b>Earnings per equity share (for continuing &amp; discontinued operation)</b>						
	Basic	0.48	0.66	1.39	1.62	4.07	2.43
	Diluted	0.48	0.66	1.39	1.62	4.07	2.43



**Arvee Laboratories (India) Limited.**

Formerly known as Arvee Laboratories (India) Pvt. Ltd.  
403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,  
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.  
Phone: +91- 2717-430479 | +91- 2717-410819  
e-mail: info@arveelabs.com, Website: www.arveelabs.com  
CIN No. :- L24231GJ2012PLC068778.



**Notes :**

- 1 The aforesaid Financial Results for the quarter and Nine Month ended December 31, 2021 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at its Meeting held on Tuesday, February 8, 2022. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- 2 The aforesaid Financial Results for the quarter and Nine Month ended December 31, 2021 have been prepared in accordance with Companies (Indian Accounting Standard) Rule, 2015 as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 In line with Ind AS - 108 Operating Segments and basis of the review of operations being done by the Senior Management, the operations of the Company fall under the Chemicals business which is considered to be the only reportable segment by the management.
- 4 The figures for the quarter ended December 31, 2021 are the balancing figures between unaudited figures of the nine months ended December, 31 2021 and unaudited figures in respect of the half year ended September 30, 2021.
- 5 Earnings Per Share is not annualised for the quarter and Nine months ended on the periods mentioned in the above results.
- 6 The figures for the corresponding Previous period have been restated / regrouped wherever necessary, to make them comparable.

For and on behalf of Board of Directors of  
ARVEE LABORATORIES (INDIA) LIMITED

SHALIN SUDHAKARBHAI PATEL  
CHAIRMAN & MANAGING DIRECTOR

DIN: 01779902

Date: February 8, 2022

Place: Ahmedabad



---

406, Time Square, Nr. Pariseema Complex, C. G. Road, Ahmedabad - 380 006  
Phone: 26406025, 26406452 M. : 98250 44362 E-mail: jdeliwala@gmail.com

## INDEPENDENT AUDITOR'S REPORT

To,  
THE BOARD OF DIRECTORS OF  
ARVEE LABORATORIES (INDIA) LIMITED  
AHMEDABAD

**Independent Auditor's Limited Review Report on Standalone Unaudited Quarterly Period and Nine Months ended 31<sup>st</sup> December, 2021 Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**


1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of ARVEE LABORATORIES (INDIA) LIMITED ("the Company") for the quarter and nine month ended 31<sup>st</sup> December, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**FOR, JAIMIN DELIWALA & CO.  
CHARTERED ACCOUNTANTS  
FRN:0103861W**



**JAIMIN DELIWALA  
PROPRIETOR  
M. No. 044529  
UDIN: 22044529AAUVIQ2366**

Place: Ahmedabad  
Date: 08/02/2022